Comparative Immunogenicity of the Gam-COVID-Vac Vaccine under Intranasal and Intramuscular Administration

In this work, we set out to compare the immunogenicity of the Gam-COVID-Vac two-component vaccine produced by GENERIUM JSC (Russia) following its intranasal or intramuscular administration of the first or both components to BALB/c mice. The immunogenicity was evaluated according to antigen-specific IgG and IgA antibodies in the blood and bronchoalveolar fluid, the number of antigen-specific IFN-γ-producing T-lymphocytes, the number of antigen-specific IFN-γ-producing CD4 and CD8 T-lymphocytes. Intranasal administration was shown to induce the mucosal immunity, significantly exceeding both qualitatively and quantitatively the effect of intramuscular administration (by the number of animals with antigen-specific IgA antibodies and the titer of antibodies in blood serum and bronchoalveolar lavage). At the same time, intramuscular administration slightly exceeded the effect obtained under intranasal administration in terms of the total number of CD8-IFN-γ-producing lymphocytes.

1. Semenov B.F., Zverev V.V., Khaitov R.М. Prognoz razvitia vaktsinoprophilaktiki v pervie desiatiletia XXI veka [Forecast for the development of vaccine prevention in the first decades of the 21st century]. Pediatric pharmacology. 2009;6(5):96–106. (In Russian).

2. Afkhami S., D’Agostino M.R., Zhang A., Stacey H.D., Marzok A., et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185:896–915. DOI: 10.1016/j.cell.2022.02.005.

3. Chavda V.P., Vora L.K., Pandya A.K., Patravale V.B. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov. Today. 2021;26(11):2619–2636. DOI: 10.1016/j.drudis.2021.07.021.

4. Gao J., Mese K., Bunz O., Ehrhardt A. State-of-the-art human adenovirus vectorology for therapeutic approaches. FEBS Lett. 2019;593(24):3609–3622. DOI: 10.1002/1873-3468.13691.

5. Hassan A.O., Kafai N.M., Dmitriev I.P., Fox J.M., Smith B.K., et al. A Single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183(1):169–184.

6. Immunogenicity testing of therapeutic protein products — developing and validating assays for anti-drug antibody detection. Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2019.

7. Khurana S., Coyle E.M., Dimitrova M., Castellino F., Nicholson K., et al. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. PLoS One. 2014;9(4):e95496. DOI: 10.1371/journal.pone.0095496.

8. Leroux-Roels I., Roman F., Forgus S., Maes C., De Boever F., et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine. 2010;28(3):849–857. DOI: 10.1016/j.vaccine.2009.10.017.

9. Lv H., Wu N.C., Tsang O.T. Yuan M., Perera R.A., et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 2020;31(9):107725. DOI: 10.1016/j.celrep.2020.107725.

10. Miquel-Clopés A., Bentley E.G., Stewart J.P., Carding S.R. Mucosal vaccines and technology. Clin. Exp. Immunol. 2019;196(2):205–214. DOI: 10.1111/cei.13285.

11. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008;48(5):1267–1281.

12. Smith T.R.F., Patel A., Ramos S., Dustin E., Zhu X., et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 2020;11(1):2601. DOI: 10.1038/s41467-020-16505-0.

13. van der Ley P.A., Zariri A., van Riet E., Oosterhoff D., Kruiswijk C.P. An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection. Front Immunol. 2021;12:781280. DOI: 10.3389/fimmu.2021.781280.

14. Wu S., Zhong G., Zhang J., Shuai L., Zhang Z., et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 2020;11(1):4081. DOI: 10.1038/s41467-020-17972-1.

15. Zhu F.-C., Li Y.-H., Guan X.-H., Hou L.-H., Wang W.-J., et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845– 1854. DOI: 10.1016/S0140-6736(20)31208-3.